Translational Metabolomics Shared Resource (TraMSR)

The Translational Metabolomics Shared Resource supports cancer metabolism research, spanning from the analysis of molecules to organelles, to cells and tissues.

Scheduling, Location, and Hours of Operation

Mass Spectrometry: Translational and Biomedical Research Center, 2nd floor
Redox and Bioenergetics: MACC Fund Research Center, 2nd floor
Preclinical and Clinical Imaging: Medical Imaging Research Center, 1st floor
Monday–Friday from 8 a.m.-5 p.m.
Submit a TraMSR iLab request

Services and Technologies

TraMSR provides expertise and services in 1) mass spectrometry (MS) analyses of the tumor metabolome; 2) bioenergetic and redox function analyses; 3) imaging of preclinical models; and 4) quantitative MRI-based clinical response assessments for monitoring patients on clinical trials.  

Mass Spectrometry
  • MS sample preparation
  • MS instrumentation: Bruker timsTOF Flex MALDI imaging; Thermo Exploris 240, Waters XEVO
  • MS-based omics analysis: lipidomics, glycomics, glycoproteomics, metabolomics
Redox and Bioenergetics
  • Redox: ROS measurements; GSH/GSSG measurements; redox immunoblotting
  • Metabolism: metabolic pathway profiling; mitochondrial oxygen consumption; glycolytic function; mitochondrial membrane potential; metabolic reprogramming
  • Instrumentation: Agilent Seahorse extracellular flux analyzers; HPLC and UHPLC systems; electron paramagnetic resonance (EPR) and luminescence spectrometers
Preclinical Imaging
  • IVIS SpectrumCT: small animal bioluminescence and fluorescence, low dose X ray microCT and Cherenkov Luminescence imaging
  • Small animal near-infrared (NIR) and short-wave infrared imaging (SWIR)
Clinical Imaging
  • Patient tumor and lymph node measurements and volumetrics
  • Clinical trial level reporting and audit support
  • Cloud-based image repository and tools



Peter LaViolette, PhD

Director, Translational Metabolomics Shared Resource (TraMSR)

Notable Publications

Regulation of immunomodulatory networks by Nrf2-activation in immune cells: Redox control and therapeutic potential in inflammatory diseases. (Pant T, Uche N, Juric M, Zielonka J, Bai X) Redox Biol 2024 Apr;70:103077. PMID: 38359749; PMCID: PMC10877431; DOI: 10.1016/j.redox.2024.103077; Scopus ID: 2-s2.0-85185554817

Health position paper and redox perspectives - Disease burden by transportation noise. (Sørensen M, Pershagen G, Thacher JD, Lanki T, Wicki B, Röösli M, Vienneau D, Cantuaria ML, Schmidt JH, Aasvang GM, Al-Kindi S, Osborne MT, Wenzel P, Sastre J, Fleming I, Schulz R, Hahad O, Kuntic M, Zielonka J, Sies H, Grune T, Frenis K, Münzel T, Daiber A) Redox Biol 2024 Feb;69:102995. PMID: 38142584; PMCID: PMC10788624; DOI: 10.1016/j.redox.2023.102995; Scopus ID: 2-s2.0-85180606610

Carvedilol Phenocopies PGC-1α Overexpression to Alleviate Oxidative Stress, Mitochondrial Dysfunction and Prevent Doxorubicin-Induced Toxicity in Human iPSC-Derived Cardiomyocytes. (Uche N, Dai Q, Lai S, Kolander K, Thao M, Schibly E, Sendaydiego X, Zielonka J, Benjamin IJ) Antioxidants (Basel) 2023 Aug 09;12(8). PMID: 37627583; PMCID: PMC10451268; DOI: 10.3390/antiox12081585; Scopus ID: 2-s2.0-85169136890

Developing small-diameter vascular grafts with human amniotic membrane: long-term evaluation of transplantation outcomes in a small animal model. (Wang B, Wang X, Kenneth A, Drena A, Pacheco A, Kalvin L, Ibrahim ES, Rossi PJ, Thatcher K, Lincoln J) Biofabrication 2023 Jan 30;15(2). PMID: 36626826; DOI: 10.1088/1758-5090/acb1da; Scopus ID: 2-s2.0-85147095444

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256. PMID: 36106394; PMCID: PMC9827178; DOI: 10.3324/haematol.2022.281309; Scopus ID: 2-s2.0-85145424654

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. (Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M) Adv Sci (Weinh) 2022 Apr;9(12):e2101267. PMID: 35243806; PMCID: PMC9036031; Scopus ID: 2-s2.0-85125564839 

Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352. PMID: 34380633; PMCID: PMC8530981; Scopus ID: 2-s2.0-85116424540

Pertuzumab and trastuzumab for HER2-positive, metasttic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 Sep;22(9):1290-1300. PMID: 34339623; DOI: 10.1016/S1470-2045(21)00336-3; Scopus ID: 2-s2.0-85113412076

Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. (Gao X, Qin S, Wu Y, Chu C, Jiang B, Johnson RH, Kuang D, Zhang J, Wang X, Mehta A, Tew KD, Leone GW, Yu XZ, Wang H) J Clin Invest 2021 Aug 16;131(16). PMID: 34255748; PMCID: PMC8363288; Scopus ID: 2-s2.0-85113146308 

WDR26 and MTF2 are therapeutic targets in multiple myeloma. (Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S) J Hematol Oncol 2021 Dec 07;14(1):203. PMID: 34876184; PMCID: PMC8650373; Scopus ID: 2-s2.0-85120899924 

AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism. (Palma FR, Ratti BA, Paviani V, Coelho DR, Miguel R, Danes JM, Zaichik SV, de Abreu AL, Silva SO, Chen Y, Silverstein RL, Karan U, Jones DP, Bonini MG) Oncogene 2021 Sep;40(36):5455-5467. PMID: 34290400; PMCID: PMC8669831; DOI: 10.1038/s41388-021-01943-x; Scopus ID: 2-s2.0-85110982210